Rheumatology/Arthritis Market Research Reports & Industry Analysis
Some evidence suggests that excessive immune responses may be due to glucocorticoid resistance in target tissues. For example, the number of glucocorticoid receptors in circulating leukocytes is decreased 50% in patients with RA. This decrease in receptors would prevent adequate suppression of leukocyte activity and could further enhance inflammation.Rheumatologists remain the most up-to-date health professionals in autoimmune disease treatment. Early intervention has been noted by nearly all in the field as the single most important factor in treatments and continued quality of life. New advancements in risk factors, diagnosis, and therapies have made it possible for rheumatologist to treat these conditions successfully with the best possible outcomes.
Successful treatment of autoimmune diseases have resulted from a growing array of therapies available to specialists. Symptomatic treatments have traditionally been used for patients with rheumatoid arthritis, lupus and other autoimmune disorders. While these treatments are still used regularly, new disease-modifying therapies have produced the most impressive results in treating these diseases. Additionally, combination therapies continue to grow in preference and offer exciting results in disease management.
Rheumatology/Arthritis Industry Research & Market Reports
-
Global Rheumatoid Arthritis Drugs Market 2018-2022
... of action and serve as promising molecules for the successful treatment of RA. Technavio’s analysts have predicted that the rheumatoid arthritis drugs market will register a CAGR of close to 8% by 2022. Market Overview ... Read More
-
Competitor Landscape: Rheumatoid Arthritis
... Highlights from the report - If the results of the Phase II MANTA safety trial are required by the FDA prior to filing for regulatory approval of filgotinib for Rheumatoid Arthritis (RA), this could delay ... Read More
-
Global Rheumatoid Arthritis Partnering 2012 to 2018
... companies.• Trends in partnering deals • Top deals by value • Deals listed by company A-Z, industry sector, stage of development, technology typeThe report provides understanding and access to the partnering deals and agreements entered ... Read More
-
Global Rheumatology Therapeutics Market 2018-2022
... sclerosis. Technavio’s analysts forecast the Global Rheumatology Therapeutics Market to grow at a CAGR of 4.24% during the period 2018-2022. Covered in this report The report covers the present scenario and the growth prospects of ... Read More
-
Digital Landscape: Rheumatoid Arthritis
... The geographic scope of the report is the United States, EUCAN (Canada and the 5EU countries - UK, Germany, France, Italy & Spain). Key Highlights US Patients: AbbVie offers the strongest support for RA patients ... Read More
-
KOL Perspectives: BTK Inhibitors in RA
... Phase IItrial design Impact of poseltinib discontinuation on existing perception of BTK inhibitors in RA Key Highlights Of the named BTK inhibitors, KOLs demonstrated the greatest awareness of BMS-986142, despite its lack of Phase II ... Read More
-
KOL Perspectives: Upadacitinib for Rheumatoid Arthritis
... & safety of upadacitinib in the SELECT COMPARE trial (csDMARD-IR patients) Efficacy & safety of upadacitinib as a monotherapy in SELECT MONOTHERAPY trial (MTX-IR patients) Views on dose response for upadacitinib Key Highlights Majority of ... Read More
-
Rheumatoid Arthritis Global Clinical Trials Review, H2, 2018
... line data relating to the clinical trials on Rheumatoid Arthritis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical ... Read More
-
KOL Perspectives: Treatment strategies for pregnant RA patients
... pregnant RA patients Certolizumab -use in pregnant RA patients Other anti-TNFs -use in pregnant RA patients IL-6 inhibitors -use in pregnant RA patients Abatacept -use in pregnant RA patients JAK inhibitors -use in pregnant RA ... Read More
-
Rheumatoid Arthritis - Pipeline Review, H1 2018
... landscape. Rheumatoid arthritis (RA) is an autoimmune chronic disorder that eventually leads to destruction of bones causing deformities. Signs and symptoms of rheumatoid arthritis include tender, warm, swollen joints, fatigue, and fever and weight loss. ... Read More
-
Global Rheumatoid Arthritis Drugs Market - Segmented by Type of Molecule, Drug Class, Sales Channel, and Geography - Growth, Trends, and Forecast (2018 - 2023)
... register a CAGR of 10.5% during the forecast period of 2018-2023. Rheumatoid Arthritis (RA) is an auto-immune disease that can cause joint pain and damage all over the body. As per the estimates of the ... Read More
-
Global Rheumatoid Arthritis Therapeutics Market Research Report 2018
... market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China). The report firstly introduced the Rheumatoid Arthritis Therapeutics basics: ... Read More
-
Rheumatoid Arthritis Pricing, Reimbursement & Market Access 2018
... America, Europe (EU5), Asia-Pacific and BRIC markets. The report also outlines the historical and current healthcare status for the selected markets with respect to the expenditures and the health system that govern medical access. With ... Read More
-
C-Reactive Protein (CRP) Test Market Size, Share & Trends Analysis Report By Assay Type, By Detection Range, By Disease Area (Cardiovascular Disease, Cancer, Rheumatoid Arthritis), By End Use, And Segment Forecasts, 2018 - 2025
... The global c-reactive protein (CRP) testing market size is expected to reach USD 1.77 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 1.3% during the forecast ... Read More
-
Drugs for Rheumatoid Arthritis: Global Markets to 2022
... Report Includes: - 95 data tables - An overview of the global rheumatoid arthritis drugs market - Analyses of global market trends, with data from 2016 and 2017, and projections of compound annual growth rates ... Read More
-
Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2023 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs
... and currently incurable autoimmune disease that primarily affects the joints. It is characterized by synovial inflammation and gradual bone erosion over many years. Disease progression results in stiffness and pain, especially in the hands and ... Read More
-
Rheumatoid Arthritis: KOL Insight [2018]
... however, Eli Lilly/Incyte’s Olumiant (baricitinib) has managed to get first-to-market advantage in Europe. KOL’s weigh in on how Olumiant is faring in the EU, how its availability is impacting Xeljanz, as well as its chances ... Read More
-
Global and Chinese Joint protection Industry, 2018 Market Research Report
... market. The report provides key statistics on the market status of the Joint protection manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Firstly, the report provides ... Read More
-
Rheumatoid Arthritis Therapeutics Market Size Analysis Report By Molecule Type (Biopharmaceuticals (Biologics, Biosimilars), Pharmaceuticals), By Sales Channel (Prescription, OTC), And Segment Forecasts, 2018 - 2025
... to reach USD 30.4 billion by 2025, according to a new report by Grand View Research, Inc., expanding at a CAGR of 4.6% during the forecast period. Some of the key trends driving the market ... Read More
-
Rheumatology Therapeutics Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024
... report predicts the global rheumatology therapeutics market to grow with a CAGR of 2.52 % over the period of 2018 - 2024. The study on rheumatology therapeutics market covers the analysis of the leading geographies ... Read More
-
KOL Perspectives: IL-6 inhibitors in Rheumatoid Arthritis
... - Current or anticipated future use of sarilumab in RA Current use of tocilizumab in RA Expected future change to sarilumab & tocilizumab use Comparison of sarilumab & tocilizumab clinical profile in RA Non-clinical differentiating ... Read More
-
The 2019-2024 World Outlook for Rheumatology Therapeutics
... industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge ... Read More
-
The 2019-2024 World Outlook for Rheumatoid Arthritis (RA) Monoclonal Antibodies (mAb)
... are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These ... Read More
-
The 2019-2024 World Outlook for Rheumatoid Arthritis Diagnosis Tests
... latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the ... Read More
-
The 2019-2024 World Outlook for Rheumatoid Arthritis Autoimmune Disorder Diagnostics
... for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks ... Read More
